Mizuho Markets Americas LLC Has $16.21 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Mizuho Markets Americas LLC boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 210,768 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,774 shares during the period. Mizuho Markets Americas LLC owned 0.94% of ANI Pharmaceuticals worth $16,208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. grew its position in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the period. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth approximately $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals during the second quarter worth approximately $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ:ANIP opened at $78.53 on Friday. The company has a 50 day moving average price of $81.26 and a two-hundred day moving average price of $79.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The company has a market capitalization of $1.79 billion, a PE ratio of 19.88 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period last year, the firm posted $1.70 earnings per share. The business’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total value of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total value of $220,374.00. Following the completion of the sale, the senior vice president owned 78,696 shares of the company’s stock, valued at $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 85,179 shares of company stock valued at $6,722,596. Company insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim reissued a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $105.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.